In its 13th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group (“Working Group”) documents research and development spending for the calendar year 2016 and analyzes funding trends spanning 16 years.
Between 2000 and 2016, the Working Group has tracked over US$17 billion in investment towards biomedical HIV prevention research and development (R&D). The 2016 report analyzes over 600 donor-identified disbursements, as well as R&D spending trends for the following prevention options: AIDS vaccines, microbicides, pre-exposure prophylaxis (PrEP), treatment as prevention (TasP), medical male circumcision (VMMC), female condoms, prevention of vertical transmission (PMTCT) and HSV-2 vaccines. Cure research and therapeutic vaccine investments were also tracked as part of a comprehensive analysis of the HIV R&D landscape.
Keywords: AVAC, HIV, prevention, treatment, funding